TAFRO Syndrome Mimicking Solid Cancer and Successfully Treated by Tocilizumab: A Case and Literature Review
TAFRO syndrome, or now formally termed idiopathic multicentric Castleman disease (iMCD) with thrombocytopenia, anasarca, fever, renal insufficiency or reticulin fibrosis, and organomegaly (iMCD-TAFRO), describes a unique subtype of iMCD. Hypersecretion of pro-inflammatory cytokines, such as interleu...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-10-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00021 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591053886062592 |
|---|---|
| author | Pei-An Fu Chia-Chi Wu Ya-Ting Hsu |
| author_facet | Pei-An Fu Chia-Chi Wu Ya-Ting Hsu |
| author_sort | Pei-An Fu |
| collection | DOAJ |
| description | TAFRO syndrome, or now formally termed idiopathic multicentric Castleman disease (iMCD) with thrombocytopenia, anasarca, fever, renal insufficiency or reticulin fibrosis, and organomegaly (iMCD-TAFRO), describes a unique subtype of iMCD. Hypersecretion of pro-inflammatory cytokines, such as interleukin-6, plays a critical role in this disease. Several anti-inflammatory medications are used for treatment, such as tocilizumab, siltuximab, and rituximab, and they have demonstrated efficacy in some cases; however, the disease remains incurable. Here, we report a 56-year-old woman who presented with ileus and progressive ascites formation. She received several operations for suspected secondary peritonitis, but thrombocytopenia, lymphadenopathy, and anasarca progressed. It took 1 year to reach the diagnosis of iMCD-TAFRO, and tocilizumab was given soon after the diagnosis. After tocilizumab treatment, her symptoms improved dramatically. Due to the heterogeneous clinical manifestations of iMCD-TAFRO, awareness of iMCD-TAFRO and a multidisciplinary team approach are required for a timely and accurate diagnosis of iMCD-TAFRO. |
| format | Article |
| id | doaj-art-b69e217a13754ccf92f6664cf7297518 |
| institution | Kabale University |
| issn | 2311-3006 |
| language | English |
| publishDate | 2023-10-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Cancer Research and Practice |
| spelling | doaj-art-b69e217a13754ccf92f6664cf72975182025-01-23T05:09:50ZengWolters Kluwer Medknow PublicationsJournal of Cancer Research and Practice2311-30062023-10-0110416116410.4103/ejcrp.eJCRP-D-23-00021TAFRO Syndrome Mimicking Solid Cancer and Successfully Treated by Tocilizumab: A Case and Literature ReviewPei-An FuChia-Chi WuYa-Ting HsuTAFRO syndrome, or now formally termed idiopathic multicentric Castleman disease (iMCD) with thrombocytopenia, anasarca, fever, renal insufficiency or reticulin fibrosis, and organomegaly (iMCD-TAFRO), describes a unique subtype of iMCD. Hypersecretion of pro-inflammatory cytokines, such as interleukin-6, plays a critical role in this disease. Several anti-inflammatory medications are used for treatment, such as tocilizumab, siltuximab, and rituximab, and they have demonstrated efficacy in some cases; however, the disease remains incurable. Here, we report a 56-year-old woman who presented with ileus and progressive ascites formation. She received several operations for suspected secondary peritonitis, but thrombocytopenia, lymphadenopathy, and anasarca progressed. It took 1 year to reach the diagnosis of iMCD-TAFRO, and tocilizumab was given soon after the diagnosis. After tocilizumab treatment, her symptoms improved dramatically. Due to the heterogeneous clinical manifestations of iMCD-TAFRO, awareness of iMCD-TAFRO and a multidisciplinary team approach are required for a timely and accurate diagnosis of iMCD-TAFRO.https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00021idiopathic multicentric castleman diseasetafro syndrometocilizumab |
| spellingShingle | Pei-An Fu Chia-Chi Wu Ya-Ting Hsu TAFRO Syndrome Mimicking Solid Cancer and Successfully Treated by Tocilizumab: A Case and Literature Review Journal of Cancer Research and Practice idiopathic multicentric castleman disease tafro syndrome tocilizumab |
| title | TAFRO Syndrome Mimicking Solid Cancer and Successfully Treated by Tocilizumab: A Case and Literature Review |
| title_full | TAFRO Syndrome Mimicking Solid Cancer and Successfully Treated by Tocilizumab: A Case and Literature Review |
| title_fullStr | TAFRO Syndrome Mimicking Solid Cancer and Successfully Treated by Tocilizumab: A Case and Literature Review |
| title_full_unstemmed | TAFRO Syndrome Mimicking Solid Cancer and Successfully Treated by Tocilizumab: A Case and Literature Review |
| title_short | TAFRO Syndrome Mimicking Solid Cancer and Successfully Treated by Tocilizumab: A Case and Literature Review |
| title_sort | tafro syndrome mimicking solid cancer and successfully treated by tocilizumab a case and literature review |
| topic | idiopathic multicentric castleman disease tafro syndrome tocilizumab |
| url | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00021 |
| work_keys_str_mv | AT peianfu tafrosyndromemimickingsolidcancerandsuccessfullytreatedbytocilizumabacaseandliteraturereview AT chiachiwu tafrosyndromemimickingsolidcancerandsuccessfullytreatedbytocilizumabacaseandliteraturereview AT yatinghsu tafrosyndromemimickingsolidcancerandsuccessfullytreatedbytocilizumabacaseandliteraturereview |